Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yip, A. G.
Right arrow Articles by Farrer, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yip, A. G.
Right arrow Articles by Farrer, L. A.
Related Collections
Right arrow Alzheimer's disease
Right arrow All epidemiology
Right arrow Risk factors in epidemiology
NEUROLOGY 2005;65:259-265
© 2005 American Academy of Neurology

APOE, vascular pathology, and the AD brain

A. G. Yip, MD, PhD, A. C. McKee, MD, R. C. Green, MD, MPH, J. Wells, PhD, H. Young, BA, L. A. Cupples, PhD and L. A. Farrer, PhD

From the Departments of Medicine (Genetics Program) (Drs. Yip, Green, and Farrer), Neurology (Drs. McKee, Green, Wells, and Farrer), and Genetics & Genomics (Dr. Farrer), Boston University School of Medicine; Departments of Epidemiology (Drs. Green and Farrer) and Biostatistics (Drs. Cupples and Farrer), Boston University School of Public Health; and Edith Nourse Rogers Memorial Veterans Hospital (Drs. McKee and Wells, and H. Young), Bedford, MA.

Address correspondence and reprint requests to Dr. Lindsay A. Farrer, Genetics Program, Boston University School of Medicine, 715 Albany Street L-320, Boston, MA 02118; e-mail: farrer{at}bu.edu

Objective: To use neuropathologic data to examine the association between APOE genotype and cerebrovascular lesions commonly found in Alzheimer disease (AD), as well as neuritic senile plaque (SP) and neurofibrillary tangle (NFT) burden.

Methods: The sample comprised brains from 96 men and 3 women who fulfilled NIA-Reagan criteria for intermediate to high likelihood of AD. Region-specific and global measures of gross cerebrovascular disease, arteriolosclerosis, white matter lesions, microinfarcts, amyloid angiopathy, neuritic SP, and NFT burden were compared among those who had at least one APOE-{varepsilon}4 vs those who did not. Pairwise rank-order correlations between measures were calculated. The association between APOE {varepsilon}4 status and measures of vascular and AD pathology, adjusting for age at death, sex, brain weight, and Braak stage, were evaluated.

Results: APOE-{varepsilon}4 was not associated with gross cerebrovascular pathology. Compared to those who were negative, brains from {varepsilon}4 individuals had a greater degree of small vessel arteriolosclerosis (p = 0.04) and perivascular macrophage infiltration (p = 0.06), but not other markers of small vessel disease or white matter myelin loss. Microinfarcts in the deep nuclei were associated with {varepsilon}4 (p = 0.009), whereas cortical and subcortical microinfarcts were not. There was a trend toward association between APOE genotype and amyloid angiopathy (p = 0.08), and {varepsilon}4 was associated with neuritic SP burden, but not NFT.

Conclusion: APOE-{varepsilon}4 is associated with small vessel arteriolosclerosis, microinfarcts of the deep nuclei, neuritic senile plaque density, and amyloid angiopathy in patients with autopsy-proven Alzheimer disease (AD). These results suggest a role for {varepsilon}4 in some of the microvascular changes commonly found in AD and are consistent with a potential amyloidogenic role for {varepsilon}4.


Supported by Alzheimer’s Association grant NIRG-03-5874, a VA Merit Award, and NIH grants P30 AG13846, R01 AG09029, and RO1 HG/AG02213.

Received November 18, 2004. Accepted in final form April 5, 2005.




This article has been cited by other articles:


Home page
NeurologyHome page
D. A. Bennett, P. L. De Jager, S. E. Leurgans, and J. A. Schneider
Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles
Neurology, April 28, 2009; 72(17): 1495 - 1503.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
K. T. Cuenco, K. L. Lunetta, C. T. Baldwin, A. C. McKee, J. Guo, L. A. Cupples, R. C. Green, P. H. St. George-Hyslop, H. Chui, C. DeCarli, et al.
Association of Distinct Variants in SORL1 With Cerebrovascular and Neurodegenerative Changes Related to Alzheimer Disease
Arch Neurol, December 1, 2008; 65(12): 1640 - 1648.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
E. G. Stopa, P. Butala, S. Salloway, C. E. Johanson, L. Gonzalez, R. Tavares, V. Hovanesian, C. M. Hulette, M. P. Vitek, and R. A. Cohen
Cerebral Cortical Arteriolar Angiopathy, Vascular Beta-Amyloid, Smooth Muscle Actin, Braak Stage, and APOE Genotype
Stroke, March 1, 2008; 39(3): 814 - 821.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
C Exley and M M Esiri
Severe cerebral congophilic angiopathy coincident with increased brain aluminium in a resident of Camelford, Cornwall, UK
J. Neurol. Neurosurg. Psychiatry, July 1, 2006; 77(7): 877 - 879.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
P. M. Erlich, K. L. Lunetta, L. A. Cupples, M. Huyck, R. C. Green, C. T. Baldwin, L. A. Farrer, and for the MIRAGE Study Group
Polymorphisms in the PON gene cluster are associated with Alzheimer disease
Hum. Mol. Genet., January 1, 2006; 15(1): 77 - 85.
[Abstract] [Full Text] [PDF]


Home page
J Geriatr Psychiatry NeurolHome page
L. F. Jarvik and D. Blazer
Children of Alzheimer Patients: An Overview
J Geriatr Psychiatry Neurol, December 1, 2005; 18(4): 181 - 186.
[PDF]


Home page
J. Neurosci.Home page
R. A. Velliquette, T. O'Connor, and R. Vassar
Energy Inhibition Elevates {beta}-Secretase Levels and Activity and Is Potentially Amyloidogenic in APP Transgenic Mice: Possible Early Events in Alzheimer's Disease Pathogenesis
J. Neurosci., November 23, 2005; 25(47): 10874 - 10883.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.